RESUMEN
OBJECTIVE: Cone Beam Computed Tomography (CBCT) was used to observe and describe the distribution of canalis sinuosus (CS) in the Chinese population and the location of CS in the maxillary alveolar bone, so as to help oral surgeons evaluate the intraoperative risk and prognosis before maxillary surgery and reduce the complications caused by the injury of this structure in anterior surgery. PATIENTS AND METHODS: CBCT images of 600 patients admitted from 2021 to 2022 were collected to observe the anatomical structure of CS in the maxillary region. The following parameters were recorded: age, sex, number of CS, left and right distribution of CS, CS diameter, and location. Statistical analysis was performed on all of the collected data. RESULTS: The discovery rate of CS in this study was 59.75%, and it is commonly found in the lateral incisor area (64.82%). No significant difference can be found in the presence and number of CS in different gender and age groups (p>0.05). CONCLUSIONS: The use of high-resolution CBCT before implantation is of irreplaceable significance in the diagnosis and analysis of CS, which is conducive to reducing implantation complications and failure rate. The incidence of CS was independent of age or sex, while the location of CS was statistically significant.
Asunto(s)
Tomografía Computarizada de Haz Cónico , Maxilar , Humanos , Tomografía Computarizada de Haz Cónico/métodos , Maxilar/diagnóstico por imagen , Maxilar/cirugía , Recolección de Datos , Implantación del Embrión , Tracto GastrointestinalRESUMEN
A total of 1 295 516 dried blood spots were collected from newborns in Hainan Province from 2007 to 2019 who participated in the screening of neonatal diseases, and 43 cases of hyperphenylalaninemia were diagnosed. Among the 43 cases, 8 cases were confirmed to have tetrahydrobiopterin deficiency (4 males and 4 females). The incidence of tetrahydrobiopterin deficiency among newborns in Hainan Province was 6.2/1 million. Six mutations in the PTS gene were detected among 7 cases; the mutations were as follows: c.317C>T, c.286G>A, c.259C>T, c.155A>G, c.84+291A>G and c.83+1777T>G. A homozygous mutation at c.41T>C site of QDPR gene was detected in one case. Overall, it's found that the incidence of tetrahydrobiopterin deficiency in newborn populations in Hainan Province is low, and PTS gene mutations account for the largest proportion of cases of tetrahydrobiopterin deficiency within the study population.
Asunto(s)
Fenilcetonurias , Femenino , Pruebas Genéticas , Humanos , Incidencia , Recién Nacido , Masculino , Tamizaje Masivo , Mutación , Fenilcetonurias/diagnóstico , Fenilcetonurias/epidemiología , Fenilcetonurias/genéticaRESUMEN
The protein kinase B (Akt)/mammalian target of rapamycin (mTOR)/p70 ribosomal S6 protein kinase (p70S6K) signaling pathway, as a central controller of cell growth, proliferation, survival, and differentiation in response to extracellular signals, growth factors, nutrient availability, energy status of the cell, and stress, has recently gained attention in neuroscience. The effects of this signaling pathway on repair of spinal cord injury (SCI), however, have not been well elucidated. ATP is increasingly recognized as an important regulator of signal transduction pathways, and plays important roles in functional recovery after nervous system injury. In the present study, we examined the ATP-induced changes of the Akt/mTOR/p70S6K signaling pathway in injured spinal cord of adult rats and potential therapeutic effects of this pathway on SCI-induced locomotor dysfunction. SCI was produced by extradural weight-drop using modified Allen's stall with damage energy of 50 g-cm force. The rats were divided into four groups: SCI plus ATP, SCI plus saline, SCI plus ATP and rapamycin, and sham-operated. Using immunostaining studies, Western blot analyses and real-time qualitative RT-PCR analyses, we demonstrated that the Akt/mTOR/p70S6K signaling pathway is present in the injured spinal cord and the expression of its components at the protein and mRNA levels is significantly elevated by exogenous administration of ATP following SCI. We observed the effectiveness of the activated Akt/mTOR/p70S6K signaling pathway in improving locomotor recovery, significantly increasing the expression of nestin, neuronal nuclei (NeuN), neuron specific enolase (NSE), and neurofilament 200 (NF200), and relatively inhibiting excessive reactive astrogliosis after SCI in a rapamycin-sensitive manner. We concluded that ATP injection produced a significant activation of the Akt/mTOR/p70S6K signaling pathway in the injured spinal cord and that enhancement of rapamycin-sensitive signaling produces beneficial effects on SCI-induced motor function defects and repair potential. We suggest that modulation of this protein kinase signaling pathway activity should be considered as a potential therapeutic strategy for SCI.
Asunto(s)
Adenosina Trifosfato/fisiología , Actividad Motora , Proteínas Proto-Oncogénicas c-akt/fisiología , Proteínas Quinasas S6 Ribosómicas 70-kDa/fisiología , Traumatismos de la Médula Espinal/metabolismo , Serina-Treonina Quinasas TOR/fisiología , Adenosina Trifosfato/farmacología , Animales , Femenino , Proteínas Proto-Oncogénicas c-akt/biosíntesis , Proteínas Proto-Oncogénicas c-akt/genética , ARN Mensajero/biosíntesis , Ratas , Ratas Sprague-Dawley , Proteínas Quinasas S6 Ribosómicas 70-kDa/biosíntesis , Proteínas Quinasas S6 Ribosómicas 70-kDa/genética , Transducción de Señal , Médula Espinal/metabolismo , Traumatismos de la Médula Espinal/fisiopatología , Serina-Treonina Quinasas TOR/biosíntesis , Serina-Treonina Quinasas TOR/genéticaRESUMEN
Expression of Id-1 (inhibitors of DNA binding/differentiation protein 1) and TSP-1 (thrombospondin-1) in mucoepidermoid carcinoma and their relationship to pathological features and prognosis was studied. Moderately and poorly differentiated groups had significantly higher Id-1 positive expression rate (p<0.05) than well differentiated carcinoma. Stages III-IV showed significant increase of Id-1 positive expression rate (p<0.05) compared with stages I and II. Id-1 positive expression was significantly higher in patients with cervical lymph node metastasis or relapse at 5 years (p<0.05). After that, patients with negative Id-1 expression had significantly higher tumor-free survival than patients with positive expression (p<0.05). Correlation between the expression of Id-1 and TSP-1 in mucoepidermoid carcinoma was negative (p<0.05). Poorly differentiated groups show significantly lower TSP-1 positive expression rate than well differentiated groups (p<0.05). No significant differences of TSP-1 positive expression were detected with clinical stage. TSP-1 positive expression was significantly lower in patients with cervical lymph node metastasis or relapse at 5 years (p<0.05). After 5 years, patients with positive TSP-1 expression had significantly higher tumor-free survival than patients with negative TSP-1. Positive Id-1 expression is associated with high malignancy/poor prognosis; positive TSP-1 expression is associated with low malignancy/good prognosis. Protein expression status may help assess tumor malignancy and patient prognosis.
Asunto(s)
Carcinoma Mucoepidermoide/patología , Proteína 1 Inhibidora de la Diferenciación/análisis , Neoplasias de las Glándulas Salivales/patología , Trombospondina 1/análisis , Adulto , Anciano , Biomarcadores de Tumor/análisis , Carcinoma/patología , Carcinoma Mucoepidermoide/secundario , Diferenciación Celular , Colorantes , Supervivencia sin Enfermedad , Femenino , Estudios de Seguimiento , Regulación Neoplásica de la Expresión Génica , Humanos , Inmunohistoquímica , Metástasis Linfática/patología , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/patología , Estadificación de Neoplasias , Glándula Parótida/patología , Pronóstico , Estudios Retrospectivos , Glándula Submandibular/patología , Tasa de SupervivenciaRESUMEN
The occurrence of head and neck cancers varies worldwide. This study retrospectively analysed the incidence and types of 8646 cases of head and neck cancers in south-west China that were treated at the West China Stomatology Hospital of Sichuan University between 1953 and 2002. Overall mean patient age was 50.3 years and the overall male:female ratio was 2.38:1; mean age increased and the male:female ratio decreased over the study period. Peak incidence occurred between the ages of 40 and 60 years. Primary tumours most frequently developed in the tongue, followed by the bucca and gingiva. Histologically, squamous cell carcinomas were most frequently recorded. The parotid gland and palate were the most common locations for salivary gland tumours. Over the study period the incidence of head and neck cancers increased with time and the rate of increase was greater in females than males. The frequency of histological types and topography were similar to previous reports.
Asunto(s)
Neoplasias de Cabeza y Cuello/epidemiología , Adolescente , Adulto , Distribución por Edad , Anciano , Anciano de 80 o más Años , Niño , Preescolar , China/epidemiología , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Caracteres Sexuales , Factores de TiempoRESUMEN
The research is designed to explore the SEM-AVS concept as a tool to assess bioavailability and toxicity of heavy metals in heavily polluted river sediments. The value of AVS and SEM is in a high level and only a few benthic invertebrate are found. Abundance of benthic invertebrate has significant correlation with SEM/AVS (r= -0.913, p<0.01) and SEM-AVS (r= -0.725, p<0.05). The analytical results of MDS (Non-matric Multi-dimensional Scaling) analysis indicate the benthic community structures of seven among nine stations where the SigmaSEM(5)-AVS<0 are similar. The two facts indicate the SEM-AVS concept also is useful to heavily polluted river sediments.
Asunto(s)
Metales Pesados/metabolismo , Metales Pesados/toxicidad , Contaminantes Químicos del Agua/metabolismo , Contaminantes Químicos del Agua/toxicidad , Contaminación Química del Agua/efectos adversos , Contaminación Química del Agua/análisis , Animales , China , Monitoreo del Ambiente , Agua Dulce/análisis , Sedimentos Geológicos/análisis , Invertebrados/crecimiento & desarrollo , Sulfuros/química , Sulfuros/metabolismo , Temperatura , Microbiología del AguaRESUMEN
Hepatitis B virus (HBV)-associated nephritis has been reported worldwide. Immune complex deposition has been accepted as its pathogenesis, although the association between the presence of local HBV DNA and viral antigen and the development of nephritis remains controversial. To understand better the roles played by HBV protein expression in the kidney, the global gene expression profile was studied in the kidney tissue of a lineage of HBV transgenic mouse (#59). The mice expressed HBsAg in serum, and HBsAg and HBcAg in liver and kidney, but without virus replication. Full-length HBV genome (adr subtype, C genotype) isolated from a chronic HBV carrier was used to establish the transgenic mice #59. Similarly manipulated mice that did not express HBV viral antigens served as controls. Southern blotting, hybridization with HBV probe, and immuno-histochemical staining were used to study HBV gene expression. mRNA extracted from the kidney tissue was analyzed using Affymetrix microarrays. HBsAg and HBcAg were located mainly in the cytoplasm of tubular epithelium. Altogether 520 genes were "up-regulated" more than twofold and 76 genes "down-regulated" more than twofold in the kidney. The complement activation, blood coagulation, and acute-phase response genes were markedly "up-regulated". Compared to the controls, the level of serum C3 protein was decreased in #59 mice, while the level of C3 protein from kidney extract was increased. Results indicate that expression of HBsAg and HBcAg in tubular epithelial cells of the kidney per se can up-regulate complement-mediated inflammatory gene pathways, in addition to immune complex formation.
Asunto(s)
Glomerulonefritis Membranosa/etiología , Antígenos del Núcleo de la Hepatitis B/metabolismo , Antígenos de Superficie de la Hepatitis B/metabolismo , Virus de la Hepatitis B/metabolismo , Animales , Proteína C-Reactiva/genética , Complemento C3/genética , Citoplasma/metabolismo , Epitelio/metabolismo , Regulación de la Expresión Génica , Genoma Viral , Antígenos del Núcleo de la Hepatitis B/genética , Antígenos de Superficie de la Hepatitis B/sangre , Antígenos de Superficie de la Hepatitis B/genética , Virus de la Hepatitis B/genética , Inmunohistoquímica , Riñón/metabolismo , Túbulos Renales/metabolismo , Hígado/metabolismo , Ratones , Ratones Transgénicos , Análisis por Matrices de Proteínas , ARN Mensajero/genéticaRESUMEN
A defect in specific T cell immunity has long been assumed to be the central mechanism of persistent Hepatitis B virus (HBV) infection. Recent studies on HBV transgenic mice have suggested, however, that functional deficit of dendritic cells (DC) was an underlying cause for the T cell dysfunction. The functions of monocyte-derived DC were determined by studying 75 subjects that included chronic hepatitis B patients with low or high HBV load; antibody to hepatitis B surface antigen (anti-HBs) positive individuals who had recovered completely from previous acute HBV infection; healthy donors who had received hepatitis B vaccination and were anti-HBs positive; and immunologically naïve to HBV or the vaccine individual. Impaired interactions between monocyte-derived DC and T cells were shown in chronic HBV infection patients, especially in those with active virus replication. The dysfunctions included: (i) failure of DC to increase human leukocyte antigen (HLA-II), B7 expression and interleukin-12 secretion in responses to hepatitis B surface antigen (HBsAg), (ii) defective induction of T cell proliferative response to HBsAg, (iii) failure to activate T cells to produce cytokines and (iv) deficit in the induction of antigen specific cytotoxic T lymphocytes (CTLs). In vitro treatment of DC with tumour necrosis factor-alpha improved HLA-II and B7 expression, as well as Th cell and CTL responses. It is concluded that defective DC-T cell interactions may account for the specific T cell immune defects in chronic HBV infection. Immunotherapy that aims at restoring DC functions could offer a new opportunity for effectively managing persistent HBV infections.
Asunto(s)
Células Dendríticas/inmunología , Hepatitis B Crónica/inmunología , Linfocitos T/inmunología , Adulto , Anciano , Animales , Secuencia de Bases , Estudios de Casos y Controles , Comunicación Celular , Citocinas/biosíntesis , ADN Viral/genética , Femenino , Genes MHC Clase II , Anticuerpos contra la Hepatitis B/sangre , Vacunas contra Hepatitis B/administración & dosificación , Virus de la Hepatitis B/genética , Virus de la Hepatitis B/aislamiento & purificación , Hepatitis B Crónica/virología , Humanos , Técnicas In Vitro , Activación de Linfocitos , Masculino , Ratones , Persona de Mediana Edad , Monocitos/inmunologíaRESUMEN
Based on the recent studies of HBV strains with different replication efficiency, several new potential targets for anti-HBV replication have been presented. These include the viral and cellular regulatory factors associated with HBV replication and the process for encapsidation of viral genome and budding into endoplasmic reticulum (ER). A putative regulatory domain has been reported at the carboxyl-end of reverse transcriptase (RT) and when serine is substituted for proline at residue 652 of RT, replication efficiency of HBV is decreased. Substitution of proline for threonine at the 2798 nucleotide of the terminal protein (TP) gene, renders the mutant completely replication deficient. Expression of TP blocks the interferon (IFN) pathway and inhibits the responsive state of cells to interferons ( IFN) alpha and gamma. Interference of HBV capsid assembly drastically affects the encapsidation of viral genome, a crucial process for reverse transcription and viral DNA synthesis. Small molecules (bis-ANS) have been reported to act as a "wedge" to misdirect the polymerization of capsid, resulting in inhibition of virus replication. Another new group of compounds (HAP) has been shown to inhibit virus replication and also inhibit the assembly of viral capsid (core particle). Finally the capsids containing HBV genome are enveloped by budding into endoplasmic reticulum and release from virus infected cells, and this morphogenesis and secretion of HBV is dependent on glucosidases in the ER of host cells. Competitive inhibition of these glucosidases has been suggested as strategy against HBV replication.
Asunto(s)
Antivirales/farmacología , Virus de la Hepatitis B/efectos de los fármacos , Cápside/efectos de los fármacos , ADN Polimerasa Dirigida por ADN/química , ADN Polimerasa Dirigida por ADN/fisiología , Diseño de Fármacos , Productos del Gen pol/química , Productos del Gen pol/fisiología , Virus de la Hepatitis B/química , Humanos , ADN Polimerasa Dirigida por ARN/química , ADN Polimerasa Dirigida por ARN/fisiología , Proteínas del Envoltorio Viral/antagonistas & inhibidores , Proteínas del Envoltorio Viral/fisiología , Replicación Viral/efectos de los fármacos , Replicación Viral/genéticaRESUMEN
To explore functional domains in the hepatitis B virus (HBV) polymerase, two naturally occurring HBV isolates (56 and 2-18) with 98.7% nucleic acid sequence homology but different replication efficiencies were studied. After transfection into HepG2 cells, HBV DNA isolated from intracellular virus core particles was much higher in 56-transfected cells than in cells transfected with 2-18. The structural basis for the difference in replication efficiency between these two isolates was studied by functional domain gene substitution. The complete polymerase (P) gene and its gene segments coding for the terminal protein (TP), spacer (SP), reverse transcriptase (RT), and RNase H in 2-18 were separately replaced with their counterparts from 56 to construct full-length chimeric genomes. Cell transfection analysis revealed that substitution of the complete P gene of 2-18 with the P gene from 56 slightly enhanced viral replication. The only chimeric genome that regained the high replication efficiency of the original 56 isolate was the one with substitution of the RT gene of 2-18 with that from 56. Within the RT region, amino acid differences between isolates 2-18 and 56 were located at positions 617 (methionine versus leucine), 652 (serine versus proline), and 682 (valine versus leucine). Point mutation identified amino acid 652 as being responsible for the difference in replication efficiency. Homologous modeling studies of the HBV RT domain suggest that the mutation of residue 652 from proline to serine might affect the conformation of HBV RT which interacts with the template-primer, leading to impaired polymerase activity.
Asunto(s)
Aminoácidos/metabolismo , Virus de la Hepatitis B/enzimología , Virus de la Hepatitis B/fisiología , ADN Polimerasa Dirigida por ARN/metabolismo , Replicación Viral , Aminoácidos/química , Secuencia de Bases , Clonación Molecular , Cartilla de ADN , Genoma Viral , Virus de la Hepatitis B/genética , Modelos Moleculares , Mutagénesis Sitio-Dirigida , Conformación Proteica , ADN Polimerasa Dirigida por ARN/química , ADN Polimerasa Dirigida por ARN/genéticaRESUMEN
In hepatitis B virus (HBV)-endemic countries, the majority of hepatocellular carcinoma (HCC) arises in HBV carriers. High frequency of mutations at nucleotides 1762(A-->T) and 1764(G-->A) in the core promoter region have been described in HCC. Due to the differences in genetic backgrounds, environmental risk factors and random cellular insertion sites, it is difficult to analyze the possible roles of HBV variants detected in different HCC patients. In a follow-up cohort study, an HBsAg-positive asymptomatic carrier was diagnosed HCC within 4 years. Eleven full-length HBV isolates, three from the first serum sample obtained 4 years pre-HCC, and eight from serum sample, peri-tumor and tumor tissue post-HCC of this individual were sequenced and used to transfect HepG2 cells. When sequences were compared between pre- and post-HCC isolates, no single mutation common to all post-HCC isolates that differed from pre-HCC isolates was found. Among all 11 isolates, there were 20 predicted amino acid substitutions shared by two or more post-HCC isolates. These were located in the S(5), X(4), core(4), polymerase(4), pre-S1(2) and pre-S2(1) proteins. Possible roles of amino acid substitutions and enhanced replication efficiency in cells transfected by post-HCC isolates are discussed.
Asunto(s)
Carcinoma Hepatocelular/virología , Portador Sano/virología , Genoma Viral , Virus de la Hepatitis B/genética , Hepatitis B/virología , Neoplasias Hepáticas/virología , Sustitución de Aminoácidos , Línea Celular , Clonación Molecular , ADN Viral/biosíntesis , Estudios de Seguimiento , Virus de la Hepatitis B/aislamiento & purificación , Humanos , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Transfección , Proteínas Virales/análisis , Proteínas Virales/genéticaRESUMEN
Therapeutic efficacy of HBsAg-anti-HBs-recombinant DNA harboring hepatitis B virus (HBV) S gene complex was compared with three other therapeutic vaccine candidates (recombinant HBsAg, HBsAg complexed to anti-HBs antibodies and naked plasmid DNA encoding the HBV S gene). After four injections at 3-week intervals, the most pronounced decrease of serum HBsAg, the highest titer of anti-HBs response, the highest level of interferon-gamma produced by splenocytes and potent cytotoxicity T cell response were observed in the HBsAg-anti HBs-sDNA immunized group. Reduced expression of HBsAg in hepatocytes was also shown. The therapeutic mechanism of HBsAg-anti-HBs-DNA was speculated as modulation of HBsAg presentation via both endogenous and exogenous pathways.
Asunto(s)
Complejo Antígeno-Anticuerpo/inmunología , ADN Recombinante/inmunología , Anticuerpos contra la Hepatitis B/inmunología , Antígenos de Superficie de la Hepatitis B/inmunología , Vacunas contra Hepatitis B/uso terapéutico , Hepatitis B/terapia , Animales , Citocinas/biosíntesis , Antígenos de Superficie de la Hepatitis B/sangre , Hígado/patología , Hígado/virología , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Linfocitos T Citotóxicos/inmunologíaRESUMEN
In hepatitis B virus (HBV)-endemic countries, the majority of hepatocellular carcinoma (HCC) arises in HBV carriers. High frequency of mutations at nucleotides 1762(A-->T) and 1764(G-->A) in the core promoter region have been described in HCC. Due to the differences in genetic backgrounds, environmental risk factors and random cellular insertion sites, it is difficult to analyze the possible roles of HBV variants detected in different HCC patients. In a follow-up cohort study, an HBsAg-positive asymptomatic carrier was diagnosed HCC within 4 years. Eleven full-length HBV isolates, three from the first serum sample obtained 4 years pre-HCC, and eight from serum sample, peri-tumor and tumor tissue post-HCC of this individual were sequenced and used to transfect HepG2 cells. When sequences were compared between pre- and post-HCC isolates, no single mutation common to all post-HCC isolates that differed from pre-HCC isolates was found. Among all 11 isolates, there were 20 predicted amino acid substitutions shared by two or more post-HCC isolates. These were located in the S(5), X(4), core(4), polymerase(4), pre-S1(2) and pre-S2(1) proteins. Possible roles of amino acid substitutions and enhanced replication efficiency in cells transfected by post-HCC isolates are discussed.
Asunto(s)
Carcinoma Hepatocelular/complicaciones , Portador Sano/virología , ADN Viral/genética , Virus de la Hepatitis B , Virus de la Hepatitis B/genética , Hepatitis B/virología , Neoplasias Hepáticas/complicaciones , Proteínas Virales/genética , Sustitución de Aminoácidos , Carcinoma Hepatocelular/genética , Carcinoma Hepatocelular/inmunología , Portador Sano/sangre , Mapeo Cromosómico , Estudios de Cohortes , ARN Polimerasas Dirigidas por ADN , Progresión de la Enfermedad , Estudios de Seguimiento , Variación Genética , Hepatitis B/inmunología , Anticuerpos contra la Hepatitis B/análisis , Anticuerpos contra la Hepatitis B/inmunología , Antígenos del Núcleo de la Hepatitis B/análisis , Antígenos del Núcleo de la Hepatitis B/genética , Antígenos del Núcleo de la Hepatitis B/inmunología , Antígenos de Superficie de la Hepatitis B/análisis , Antígenos de Superficie de la Hepatitis B/genética , Antígenos de Superficie de la Hepatitis B/inmunología , Virus de la Hepatitis B/inmunología , Virus de la Hepatitis B/aislamiento & purificación , Humanos , Neoplasias Hepáticas/genética , Neoplasias Hepáticas/inmunología , Reacción en Cadena de la Polimerasa , Regiones Promotoras Genéticas , Factores de Tiempo , Transfección , Proteínas Virales/análisisRESUMEN
Human papillomavirus (HPV) is established as the cause of almost 100% of cervical carcinomas. However, the association of HPV with oral squamous cell carcinomas (SCCs) is less well understood. We examined the prevalence of HPV in oral SCCs in samples of Japanese and Chinese populations. Using in situ polymerase chain reaction (PCR) analysis (MY09 and MY11 consensus primers), HPV was detected in the nucleus of epithelia and tumor cells in oral lesions. Analysis revealed the specific presence of HPV DNA in all cases of SCC in our Japanese (10/10) and Chinese (10/10) population samples. These results suggest that HPV infection could be one of several risk factors contributing to oral SCC in Japanese and Chinese.
Asunto(s)
Carcinoma de Células Escamosas/virología , Neoplasias de la Boca/virología , Papillomaviridae/aislamiento & purificación , Infecciones por Papillomavirus/complicaciones , Infecciones Tumorales por Virus/complicaciones , China , ADN Viral/aislamiento & purificación , Humanos , Hibridación in Situ , Japón , Reacción en Cadena de la Polimerasa/métodos , PrevalenciaRESUMEN
The efficacy of cytokine therapy has been demonstrated in several viral diseases. Interferon-gamma is a cytokine that has potent antiviral property and immunomodulatory activity. To investigate the role of IFN-gamma in viral clearance during natural infection and to define the antiviral mechanism, DHBV-infected ducks was used as an animal model. To clone, express, and develop the method of quantifying DuIFN-gamma gene transcription and expression, DuIFN -gamma cDNA was amplified by RT-PCR from PHA stimulated duck PBMC. Recombinant plasmid expressing DuIFN-gamma was used to transfect COS-7, and the cell culture supernatant was analyzed by CPE inhibitory assay and MTT methods to determine the antiviral titer of IFN-gamma. The GST-DuIFN-gamma fusion protein was expressed in E.coli and purified using the GST sepharose 4B. Results indicated that the supernatant collected from COS-7 cells transfected with DuIFN-gamma cDNA was able to prevent duck fibroblasts from VSV induced CPE in a dose dependent manner. An anti-DuIFN-gamma antibody neutralized this antiviral activity.
RESUMEN
Viral hepatitis is one of the most prevalent infectious diseases in China. To date, all five types, hepatitis A, B, C, D and E have been reported in China, and the incidences of all these types are high in the Chinese population. Serological tests are mainly used for the diagnosis of hepatitis A, B, C and E in patients, epidemiological surveys and for efficacy studies of vaccines. Currently, nucleic acid-based assays are only used in research and for evaluation of antiviral and immuno-therapies.
Asunto(s)
Hepatitis Viral Humana/diagnóstico , Antivirales/uso terapéutico , China/epidemiología , Anticuerpos Antihepatitis/inmunología , Virus de la Hepatitis B/enzimología , Virus de la Hepatitis B/genética , Virus de la Hepatitis B/inmunología , Hepatitis Viral Humana/epidemiología , Hepatitis Viral Humana/inmunología , Hepatitis Viral Humana/terapia , Humanos , Mutación/genética , Estudios Seroepidemiológicos , Pruebas SerológicasRESUMEN
DNA immunization was used to compare the immunogenicity of hepatitis B virus S gene variants. Four recombinant plasmid DNAs containing the full-length virus genome with different S gene inserts were used to immunize BALB/c and C57/BL/6 mice. These inserts were cloned from 129L (residue 129, glutamine to leucine), 129H (residue 129, glutamine to histidine) 145R (residue 145, glycine to arginine) variants and the wild-type virus. The titer of hepatitis B virus core antibodies (anti-HBc) in immunized mice was used as the control for the efficiency of DNA immunization. Serum hepatitis B surface antibody (anti-HBs) titer and cytokines induced in splenocytes stimulated with hepatitis B surface antigen (HBsAg) were monitored as specific immune responses induced by different plasmid DNAs. 129L DNA induced significantly lower anti-HBs antibodies (IgG, IgG1, and IgG2a) and less interferon-gamma, compared to those in mice immunized with the 129H variant and the wild-type HBV DNA (p < 0.05). Computer modeling showed that a change from glutamine to leucine at 129 residue led to higher hydrophobicity and could result in decreased immunogenicity. Results indicate that DNA immunization can be used to compare the humoral and cellular immunogenicity among different HBV S variants.
Asunto(s)
Antígenos de Superficie de la Hepatitis B/inmunología , Vacunas contra Hepatitis B/inmunología , Virus de la Hepatitis B/inmunología , Vacunas de ADN/inmunología , Animales , Citocinas/análisis , Femenino , Variación Genética , Anticuerpos contra la Hepatitis B/biosíntesis , Antígenos de Superficie de la Hepatitis B/genética , Vacunas contra Hepatitis B/genética , Virus de la Hepatitis B/genética , Inmunización , Interferón gamma/análisis , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Plásmidos , Bazo/inmunología , Vacunas de ADN/administración & dosificaciónRESUMEN
Microbial persistent infection usually occurs due to invasion of the immune system, microbial genomic mutation or integration of microbial DNA with host chromosomal DNA. Defective host immune responses or immune tolerance are also related to persistent infection. Therapeutic vaccine is aimed at inducing specific humoral and cellular immune responses to terminate microbial persistent infection or to prevent progression of diseases. Different categories of therapeutic vaccines have been presented and the prospect of research as well as the development of novel effective therapeutic vaccines are discussed.
Asunto(s)
Infecciones/tratamiento farmacológico , Vacunas/uso terapéutico , Vacunas Bacterianas/uso terapéutico , Vacunas contra el Cáncer/uso terapéutico , Humanos , Infecciones/inmunología , Vacunas/clasificación , Vacunas Virales/uso terapéuticoRESUMEN
In a previous study, hepatitis B surface antigen (HBsAg) complexed to human anti-HBs immunoglobulins (HBIG) in excess of HBsAg was used as therapeutic vaccine to treat chronic hepatitis B patients and promising results were obtained. To study the mechanisms of this approach, mice were immunized with HBsAg or IC (immunogenic complex, i.e. HBsAg complexed with mouse polyclonal anti-HBs). Studies indicate that IC induced enhanced immune responses by increasing uptake of HBsAg through Fc receptors on antigen presenting cells and modulated HBsAg processing and presentation. This modulation led to stimulation of T cell responses, and increased production of IL-2 and IFN-gamma. Assay for antibody subclasses showed that higher ratio of IgG 2a was observed in the IC immunized group, which correlated with the production of lymphokine pattern. When alum was used as the adjuvant, though antibody response was enhanced, production of cytokines decreased. When DNA from a recombinant plasmid was added to IC as an adjuvant, the titer of anti-HBs was significantly higher than those in mice immunized only with the DNA or the IC. Since DNA immunization can induce both cellular and humoral immune responses, combined immunization using IC and DNA might serve as another type of therapeutic vaccine for viral hepatitis B.